Pharmacogenomic medications

As pharmacogenetics and pharmacogenomics are not mutually exclusive, but even sometimes display overlapping features, both disciplines are aimed at better tailoring medical therapy for a given complex disease such as essential hypertension or other CVD. In the wake of new technologies to identify candidate region for whatever phenotype, more robust and complex bioinformatic analyses are necessary to... 

The 2.9 billion letter nucleotide base pair sequence of the human genome is now available as a fundamental resource for scientific and medical discovery on many fronts [1, 2]. Pharmacogenomics (the science of individualized prevention and therapy) is no exception. 

The science of microbial genomics requires special attention, in part, because of its medical and economic importance. Even more so, microbial genomics provide important lessons for all of computational biology and comparative genomics, and therefore, microbial genomes are prototypes for the future of pharmacogenomics. 

The data contain a wealth of information. In this chapter we report the findings from five areas of inquiry (1) willingness to participate in genetic research (2) trust in various entities to perform genetic research (3) perceptions of the affordability of pharmacogenomic-based medications (4) concerns about the confidentiality of genetic information and (5) stability of views during the interview. 

The cost implications of pharmacogenomics, both at the individual and societal levels, are the subject of considerable debate, as discussed in detail in Chapter 12 of this book. One possible scenario is that pharmacogenomic-based medications will be more expensive and therefore not as widely available as pharmaceutical products intended for wider distribution (Rai, 2001 Rothstein and Epps, 2001). We attempted to determine whether members of the public believed that they would be able to afford these new pharmaceutical products. To do so, we asked the following question (Question 9) ... 

---